Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

[Image: see text] Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Konteatis, Zenon, Artin, Erin, Nicolay, Brandon, Straley, Kimberly, Padyana, Anil K., Jin, Lei, Chen, Yue, Narayaraswamy, Rohini, Tong, Shuilong, Wang, Feng, Zhou, Ding, Cui, Dawei, Cai, Zhenwei, Luo, Zhiyong, Fang, Cheng, Tang, Huachun, Lv, Xiaobing, Nagaraja, Raj, Yang, Hua, Su, Shin-San M., Sui, Zhihua, Dang, Lenny, Yen, Katharine, Popovici-Muller, Janeta, Codega, Paolo, Campos, Carl, Mellinghoff, Ingo K., Biller, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025383/
https://www.ncbi.nlm.nih.gov/pubmed/32071674
http://dx.doi.org/10.1021/acsmedchemlett.9b00509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025383/
https://www.ncbi.nlm.nih.gov/pubmed/32071674
http://dx.doi.org/10.1021/acsmedchemlett.9b00509

Ejemplares similares